Zhitong Finance APP News, Li's Pharmaceutical Factory (00950) issued an announcement regarding franchising and research and development of NVK-002. On November 12, 2020, the first patient has completed enrollment in the three-year phase III study of atropine (CHAMP) in children with deepening myopia conducted by business partner Nevakar Inc. (Nevakar).
The CHAMP study is a U.S. Food and Drug Administration (FDA) drug clinical trial aimed at assessing the ability of its lead compound NVK-002 to slow the progression of myopia in children. NVK-002 is a research patented eye drops without preservatives. It is planned to be used at night for patients aged 3 to 17 years.
NVK-002 is a new type of topical eye therapy without preservatives, which slows down the progression of myopia in children. The Phase III CHAMP study is currently underway in the United States and Europe. The CHAMP trial follows a breakthrough study in Asia that found that low-dose atropine can be used to slow the progression of myopia in children. The CHAMP is a 576-subject, sample, placebo-controlled, double-blind study designed to assess the effectiveness of NVK-002 on children's myopia progression. The study period is three years, after which patients who have been enrolled will be re-sampled for follow-up in the fourth year. On this basis, the experiment is proceeding smoothly, hoping to obtain three-year data results in 2022. Once approved, NVK-002 may become the first drug therapy to slow the progression of myopia and protect eyesight in children.
